Conclusion of non-exclusive pharmaceutical discount agreements under Section 130a(8) SGB V via an open-house model for the active substance formoterol/aclidinium bromide (WHO ATC code: R03AL05)

Summary

The notice concerns non-exclusive discount agreements for medicines containing formoterol/aclidinium bromide under Section 130a(8) of the German Social Code Book V, using an open-house model. Any interested pharmaceutical company may join during the participation period if it meets the participation requirements. There is no individual negotiation and no delivery exclusivity. The exact submission documents, deadlines and access procedure are set out in the tender documents. The agreement ends no later than 30 June 2027.